Lazertinib approved for use in combination with amivantamab for the treatment of adults with non-small cell lung cancer March 6, 2025
Share Facebook Twitter LinkedIn Pinterest Email Updates to this page Published 6 March 2025 Last updated 6 March 2025 + show all updates 6 March 2025 Added translation 6 March 2025 First published.
Lazertinib approved for use in combination with amivantamab for the treatment of adults with non-small cell lung cancer March 6, 2025
Specialised Committee on the Implementation of the Windsor Framework: Joint Statement, 6 March 2025March 6, 2025
Joint statement between Prime Minister Keir Starmer and Taoiseach Micheál Martin: 6 March 2025March 6, 2025